Related Experiment Video

Updated: May 2, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K

Association between the rs342293 polymorphism and adverse cardiac events in patients undergoing percutaneous coronary

Jolanta M Siller-Matula1, Iciar Arbesu, Bernd Jilma

  • 1Jolanta Siller-Matula, MD, PhD, Department of Cardiology, Medical University of Vienna, Austria,

Thrombosis and Haemostasis
|March 22, 2014
PubMed

Insights

The rs342293 single nucleotide polymorphism (SNP) is linked to larger mean platelet volume (MPV). Individuals with the G-variant face a higher risk of adverse cardiovascular events after coronary stenting.

Area of Science:

  • Cardiovascular Genetics
  • Platelet Physiology
  • Pharmacogenomics

Background:

  • Single nucleotide polymorphisms (SNPs) can influence cardiovascular risk factors.
  • Mean platelet volume (MPV) is a marker associated with platelet activation and cardiovascular disease.
  • The rs342293 SNP's role in cardiovascular outcomes requires further investigation.

Purpose of the Study:

  • To investigate the association between the rs342293 SNP and cardiovascular outcomes in patients with coronary artery disease.
  • To determine if the rs342293 polymorphism influences MPV and platelet count.
  • To assess the prognostic value of the rs342293 SNP in patients undergoing percutaneous coronary intervention.

Main Methods:

  • Prospective cohort study of 404 patients with coronary artery disease.
  • Genotyping of the rs342293 polymorphism.
  • Measurement of platelet count and MPV.
  • Two-year follow-up for cardiac adverse events.

Main Results:

  • The rs342293 polymorphism was significantly associated with MPV (p<0.001) but not platelet count.
  • Carriers of the rs342293 G variant showed a higher risk of cardiac adverse events (33% vs 22%; adjusted HR=1.63, p=0.027).
  • The rs342293 SNP explained 2.9% of MPV variability (p=0.01).

Conclusions:

  • The rs342293 SNP is associated with increased MPV.
  • Carrying the G-variant of rs342293 SNP increases the risk of adverse cardiovascular outcomes in patients undergoing coronary stenting.
  • This SNP may serve as a potential biomarker for cardiovascular risk stratification.

Keywords:
Platelet aggregationgeneticmyocardial Infarctionoutcome assessment (healthcare)platelet countpolymorphism

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
943
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
2.1K